Abstract. Nine healthy men were treated with a daily dose of 5 or 10 mg of the anti-androgen cyproterone acetate. Patelet aggregability was increased in 6 of 9 men; fibrinolytic activity decreased in 7 of 7 and the fibrinolytic capacity decreased in 5 of 7 volunteers. We conclude that platelet aggregability, fibrinolytic activity and capacity may be modified by anti-androgen treatment and therefore attention should be paid to the coagulation parameters when cyproterone acetate is used.
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Increased platelet responsiveness occurs in thromboembolic disease (Acheson et al. 1972 ) ischaemic heart disease and after acute myocardial infarction (Zahavi & Dreyfuss 1969) . In animal models testosterone promotes platelet ag¬ gregabilitv (Johnson et al. 1977) , experimental arterial thrombosis (Uzunova et al. 1978) and pul¬ monary platelet aggregates (Uzunova et al. 1977) . No (Corker et al. 1978) .
Results
In the nine volunteers to whom the anti-androgen drug cyproterone acetate was administered the platelet aggregability was increased in 6, un¬ changed in 2 and decreased in 1 subject (0.02 < P < 0.05, Fig. 1 ). The fibrinolytic activity decreased in 7 of 7, whereas fibrinolytic capacity was de- 
